Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

A method for treating or inhibiting eosinophilic asthma-Chronic Obstructive Pulmonary Disease (COPD) overlap syndrome (ACOS), the method comprising administering an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist to a subject having:

• i) the IL33 variant rs1342326 but not having the intronic IL1RL1 variant rs1420101;
• or ii) both the intronic IL1RL1 variant rs1420101 and the IL33 variant rs1342326,
• wherein the IL33 antagonist comprises an IL33 trap or an antibody, or antigen-binding fragment thereof, that specifically binds to IL33;
• wherein the IL33 trap comprises a first IL33 binding domain comprising an IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising an extracellular portion of IL-1RAcP;
• wherein the IL33 antibody, or antigen-binding fragment thereof, that specifically binds to IL33 comprises the complementarity determining regions of a heavy chain comprising the amino acid sequence of SEQ ID NO:274 and the complementarity determining regions of a light chain comprising the amino acid sequence of SEQ ID NO:282;
• wherein the IL-4R antagonist comprises an antibody, or antigen-binding fragment thereof, that specifically binds to IL-4R and comprises the complementarity determining regions of a heavy chain comprising the amino acid sequence of SEQ ID NO:337 and the complementarity determining regions of a light chain comprising the amino acid sequence of SEQ ID NO:338;
• and
• wherein eosinophilic ACOS is treated or inhibited in the subject.